TrippBio is a biotechnology company focused on discovering new antiviral treatments for respiratory viruses. The company develops innovative applications of existing drugs, such as PanCytoVir™, to block virus replication and reduce hyper-inflammation. This approach aims to provide low-risk, high-efficacy therapeutic options for conditions like influenza, RSV, and COVID-19.
Funding
$180K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The global impact of respiratory viruses such as influenza, RSV, and SARS-CoV-2 results in significant morbidity and mortality, and current treatment options are limited by viral mutation, drug resistance, and a lack of effective vaccines for all strains. There is a need for broad-spectrum antiviral drugs that can address these limitations and provide effective treatment for a range of respiratory viral infections.
Solution
TrippBio is developing new applications of existing pharmaceuticals, focusing on low-risk, high-efficacy drugs to treat viral pathogens. Their lead candidate, PanCytoVir™ (probenecid), is an FDA-approved drug currently indicated for gout, which the company is repurposing as a broad-spectrum antiviral. PanCytoVir™ inhibits viral replication by targeting host proteins required for viral replication, reducing the likelihood of drug resistance. Clinical and preclinical studies have demonstrated PanCytoVir's™ efficacy against SARS-CoV-2, influenza A and B strains, and RSV. The company is also developing a novel oral suspension formulation of PanCytoVir™ to enable flexible dosing across different patient populations affected by these respiratory viruses.
Target Audience
The primary target audience includes patients infected with respiratory viruses such as COVID-19, influenza, and RSV, as well as healthcare providers seeking effective and safe treatment options for these infections.
Features
- Broad-spectrum antiviral activity against SARS-CoV-2, influenza A and B, and RSV
- Mechanism of action targets host proteins, reducing the risk of drug resistance
- Demonstrated in vitro and in vivo efficacy in preclinical studies
- Completed Phase 2 clinical trial for COVID-19 showing reduced viral load and symptom resolution
- Novel oral suspension formulation for flexible dosing
- Granted US patent for "Methods of Using Probenecid for Treatment of Coronavirus Infections"
- Potential anti-inflammatory benefits through modulation of ACE2 and targeting the PANX1 gene